Pirfenidone: A potential therapy for progressive lung allograft dysfunction?

Journal of Heart and Lung Transplantation

Volumn 32, Issue 5, 2013, Pages 574-575

  Ihle, Franziska ^a   Von Wulffen, Werner ^a   Neurohr, Claus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; PIRFENIDONE; STEROID; TACROLIMUS;

ADULT; CASE REPORT; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HIATUS HERNIA; HUMAN; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; NOTE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; STOMACH FUNDOPLICATION; TOTAL LUNG CAPACITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHIOLITIS OBLITERANS; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; FIBROSIS; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; LUNG TRANSPLANTATION; MIDDLE AGED; PYRIDONES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84876039461     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2013.02.004     Document Type: Letter

References (5)

1. Verleden SE, Vos R, Mertens V, Willems-Widyastuti A, et al. Heterogeneity of chronic lung allograft dysfunction: insights from protein expression in broncho alveolar lavage. J Heart Lung Transplant;30:667-673.
2. L. Richeldi, U. Yasothan, and P. Kirkpatrick Pirfenidone Nat Rev Drug Discov 10 2011 489 490
3. B.W. McKane, F. Fernandez, K. Narayanan, S. Marshbank, S.B. Margolin, and M. Jendrisak Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model Transplantation 77 2004 664 669
4. H. Zhou, C.W. Latham, D.S. Zander, S.B. Margolin, and G.A. Visner Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts J Heart Lung Transplant 24 2005 1577 1585
5. A. Dosanjh Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients Eur J Pharmacol 536 2006 219 222